Promising Results for Two-Drug, Long-Acting Injectable HIV Regimen

July 24, 2017

No virologic non-responders were identified in the 4-week group while just 4% were identified in the 8-week group

A two-drug, long-acting injectable regimen of HIV medications has demonstrated efficacy in maintaining HIV-1 viral suppression throughout almost two years of treatment. The results come from the ongoing LATTE-2 trial and were presented today at the 9th International AIDS Society (IAS) Conference on HIV Science, in Paris.

This Phase 2b trial assessed HIV-1 viral suppression with rilpivirine (Janssen) and cabotegravir (ViiV Healthcare) given together every 4 or 8 weeks. Participating individuals had a plasma HIV-1 RNA, <50 c/mL during a 20-week Induction Period with daily oral cabotegravir 30mg plus abacavir/lamivudine 600mg/300mg. Following induction they were randomized 2:2:1 to intramuscular injections every 4 weeks (long-acting cabotegravir 400mg plus rilpivirine 600mg; two 2-mL injections), or every 8 weeks (long-acting cabotegravir 600mg plus rilpivirine 900mg; two 3-mL injections), or to continue receiving three-drug, oral ART in the Maintenance Period.

Results showed that for those who received injections every 8 weeks, 94% (n=108) achieved viral suppression. In addition, virologic response was achieved by 87% (n=100) of patients who received injections every 4 weeks versus 84% (n=47) of patients in the oral ART group. No virologic non-responders were identified in the 4-week injection group while just 5 (n=4%) were identified in the 8-week group. 

“Results published in The Lancet strengthen the evidence that a two-drug, long-acting regimen may offer an effective and acceptable alternative for people who have achieved viral suppression but struggle with daily, oral regimens to control their HIV,” said Paul Stoffels MD, CSO, Johnson & Johnson.

Injection site reactions (ISRs) were common for…

Read the full article at the Original Source..

Back to Top